Brennan F, Flanagan M, Blake S, Cannon P
Eur J Clin Pharmacol. 1983;25(6):713-5. doi: 10.1007/BF00542507.
Nifedipine, a calcium antagonist with a predominant vasodilator action, was evaluated for the treatment of hypertension. A 20 mg-tablet, with a slower absorption and a more sustained blood-level than provided by the 10 mg-capsule was administered to 20 patients. The duration of the trial was 20 weeks. All patients achieved a significant reduction in both systolic (p less than 0.05) and diastolic (p less than 0.001) blood-pressure (B.P.), but 10 patients were withdrawn before completion of the trial period. Two patients, although achieving a fall in B.P. which was significant, did not reach to target level (less than 160/90) on maximal dosage, one patient suffered a stroke due to a cerebral infarct, and seven patients were withdrawn because of side-effects due mainly to vasodilatation. The remaining 10 patients obtained a satisfactory response. In nine patients, who had achieved a satisfactory result, there was no change in plasma renin activity (P.R.A.) during chronic nifedipine administration.
硝苯地平是一种主要具有血管舒张作用的钙拮抗剂，已对其治疗高血压的效果进行了评估。给20名患者服用了一种20毫克的片剂，其吸收比10毫克胶囊更慢，血药浓度维持时间更长。试验持续时间为20周。所有患者的收缩压（p<0.05）和舒张压（p<0.001）均显著降低，但有10名患者在试验期结束前退出。两名患者虽然血压下降显著，但在最大剂量时未达到目标水平（低于160/90），一名患者因脑梗死中风，七名患者因主要由血管舒张引起的副作用而退出。其余10名患者获得了满意的反应。在9名取得满意结果的患者中，长期服用硝苯地平期间血浆肾素活性（P.R.A.）没有变化。
